nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—Triamcinolone—multiple sclerosis	0.115	0.236	CbGbCtD
Lenalidomide—PTGS2—Betamethasone—multiple sclerosis	0.0984	0.203	CbGbCtD
Lenalidomide—PTGS2—Dexamethasone—multiple sclerosis	0.0573	0.118	CbGbCtD
Lenalidomide—ABCB1—Methylprednisolone—multiple sclerosis	0.0499	0.103	CbGbCtD
Lenalidomide—ABCB1—Mitoxantrone—multiple sclerosis	0.0364	0.075	CbGbCtD
Lenalidomide—TNFSF11—leg—multiple sclerosis	0.034	0.391	CbGeAlD
Lenalidomide—ABCB1—Betamethasone—multiple sclerosis	0.0325	0.0669	CbGbCtD
Lenalidomide—ABCB1—Prednisolone—multiple sclerosis	0.032	0.066	CbGbCtD
Lenalidomide—ABCB1—Prednisone—multiple sclerosis	0.0303	0.0623	CbGbCtD
Lenalidomide—ABCB1—Dexamethasone—multiple sclerosis	0.0189	0.0389	CbGbCtD
Lenalidomide—ABCB1—Methotrexate—multiple sclerosis	0.0152	0.0313	CbGbCtD
Lenalidomide—CDH5—Adherens junctions interactions—PVRL4—multiple sclerosis	0.0144	0.149	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoclast Signaling—IFNB1—multiple sclerosis	0.00909	0.0942	CbGpPWpGaD
Lenalidomide—CDH5—Cell-cell junction organization—PVRL4—multiple sclerosis	0.00824	0.0854	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoclast Signaling—SPP1—multiple sclerosis	0.00653	0.0676	CbGpPWpGaD
Lenalidomide—CDH5—Cell junction organization—PVRL4—multiple sclerosis	0.00624	0.0646	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—PVRL4—multiple sclerosis	0.00444	0.046	CbGpPWpGaD
Lenalidomide—PTGS2—leg—multiple sclerosis	0.00443	0.0509	CbGeAlD
Lenalidomide—CDH5—medulla oblongata—multiple sclerosis	0.00416	0.0478	CbGeAlD
Lenalidomide—CDH5—midbrain—multiple sclerosis	0.0038	0.0437	CbGeAlD
Lenalidomide—CDH5—spinal cord—multiple sclerosis	0.00371	0.0426	CbGeAlD
Lenalidomide—CRBN—retina—multiple sclerosis	0.00366	0.042	CbGeAlD
Lenalidomide—Pomalidomide—TNF—multiple sclerosis	0.00348	0.608	CrCbGaD
Lenalidomide—CDH5—nervous system—multiple sclerosis	0.00313	0.0359	CbGeAlD
Lenalidomide—CDH5—central nervous system—multiple sclerosis	0.00301	0.0346	CbGeAlD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—VCAM1—multiple sclerosis	0.00297	0.0307	CbGpPWpGaD
Lenalidomide—CDH5—cerebellum—multiple sclerosis	0.00294	0.0338	CbGeAlD
Lenalidomide—CRBN—medulla oblongata—multiple sclerosis	0.00264	0.0304	CbGeAlD
Lenalidomide—CRBN—midbrain—multiple sclerosis	0.00242	0.0278	CbGeAlD
Lenalidomide—CDH5—brain—multiple sclerosis	0.00239	0.0275	CbGeAlD
Lenalidomide—CRBN—spinal cord—multiple sclerosis	0.00236	0.0271	CbGeAlD
Lenalidomide—Thalidomide—TNF—multiple sclerosis	0.00224	0.392	CrCbGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—ICAM1—multiple sclerosis	0.00202	0.0209	CbGpPWpGaD
Lenalidomide—CRBN—nervous system—multiple sclerosis	0.00199	0.0228	CbGeAlD
Lenalidomide—CRBN—central nervous system—multiple sclerosis	0.00191	0.022	CbGeAlD
Lenalidomide—CRBN—cerebellum—multiple sclerosis	0.00187	0.0215	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—TYK2—multiple sclerosis	0.00186	0.0193	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—S1PR1—multiple sclerosis	0.00185	0.0191	CbGpPWpGaD
Lenalidomide—CRBN—brain—multiple sclerosis	0.00152	0.0174	CbGeAlD
Lenalidomide—CDH5—S1P2 pathway—MAPK1—multiple sclerosis	0.00144	0.0149	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTPRK—multiple sclerosis	0.00141	0.0146	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—STAT3—multiple sclerosis	0.0013	0.0135	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—MYC—multiple sclerosis	0.00121	0.0125	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—TGFB1—multiple sclerosis	0.00119	0.0123	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—MAPK1—multiple sclerosis	0.00105	0.0108	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IL6—multiple sclerosis	0.000911	0.00943	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TBX21—multiple sclerosis	0.000907	0.00939	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—IL6—multiple sclerosis	0.000896	0.00927	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000875	0.00906	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000875	0.00906	CbGpPWpGaD
Lenalidomide—PTGS2—Fluocinonide—Methylprednisolone—multiple sclerosis	0.000833	0.159	CbGdCrCtD
Lenalidomide—PTGS2—Fluocinonide—Betamethasone—multiple sclerosis	0.00082	0.156	CbGdCrCtD
Lenalidomide—PTGS2—Fluocinonide—Dexamethasone—multiple sclerosis	0.00082	0.156	CbGdCrCtD
Lenalidomide—PTGS2—Fluocinonide—Triamcinolone—multiple sclerosis	0.000801	0.153	CbGdCrCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—TYK2—multiple sclerosis	0.000731	0.00757	CbGpPWpGaD
Lenalidomide—PTGS2—medulla oblongata—multiple sclerosis	0.00072	0.00827	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—TYK2—multiple sclerosis	0.00069	0.00714	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—MAPK1—multiple sclerosis	0.000668	0.00692	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CBLB—multiple sclerosis	0.000665	0.00689	CbGpPWpGaD
Lenalidomide—PTGS2—midbrain—multiple sclerosis	0.000658	0.00756	CbGeAlD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—multiple sclerosis	0.000649	0.00672	CbGpPWpGaD
Lenalidomide—PTGS2—spinal cord—multiple sclerosis	0.000642	0.00737	CbGeAlD
Lenalidomide—ABCB1—retina—multiple sclerosis	0.000616	0.00708	CbGeAlD
Lenalidomide—PTGS2—nervous system—multiple sclerosis	0.000541	0.00621	CbGeAlD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—multiple sclerosis	0.000539	0.00558	CbGpPWpGaD
Lenalidomide—PTGS2—central nervous system—multiple sclerosis	0.000521	0.00598	CbGeAlD
Lenalidomide—PTGS2—cerebellum—multiple sclerosis	0.000509	0.00585	CbGeAlD
Lenalidomide—PTGS2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.000503	0.0958	CbGdCrCtD
Lenalidomide—ABCB1—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000498	0.00516	CbGpPWpGaD
Lenalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.000495	0.0942	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.000495	0.0942	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.000483	0.0921	CbGdCrCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—MAPK1—multiple sclerosis	0.000465	0.00482	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—multiple sclerosis	0.000446	0.00462	CbGpPWpGaD
Lenalidomide—ABCB1—medulla oblongata—multiple sclerosis	0.000445	0.00511	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—LINGO1—multiple sclerosis	0.000444	0.00459	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—MAPK1—multiple sclerosis	0.000439	0.00455	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—multiple sclerosis	0.000434	0.00449	CbGpPWpGaD
Lenalidomide—PTGS2—brain—multiple sclerosis	0.000414	0.00475	CbGeAlD
Lenalidomide—ABCB1—midbrain—multiple sclerosis	0.000407	0.00467	CbGeAlD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—multiple sclerosis	0.000398	0.00412	CbGpPWpGaD
Lenalidomide—ABCB1—spinal cord—multiple sclerosis	0.000397	0.00456	CbGeAlD
Lenalidomide—PTGS2—Spinal Cord Injury—MBP—multiple sclerosis	0.000388	0.00402	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TAGAP—multiple sclerosis	0.000385	0.00398	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—C4A—multiple sclerosis	0.000379	0.00392	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—multiple sclerosis	0.000371	0.00384	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6—multiple sclerosis	0.000357	0.0037	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—IL6—multiple sclerosis	0.000337	0.00349	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—S1PR1—multiple sclerosis	0.000336	0.00348	CbGpPWpGaD
Lenalidomide—ABCB1—nervous system—multiple sclerosis	0.000335	0.00384	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—GPC5—multiple sclerosis	0.000327	0.00339	CbGpPWpGaD
Lenalidomide—ABCB1—central nervous system—multiple sclerosis	0.000322	0.0037	CbGeAlD
Lenalidomide—ABCB1—cerebellum—multiple sclerosis	0.000315	0.00362	CbGeAlD
Lenalidomide—ABCB1—Allograft Rejection—CXCL13—multiple sclerosis	0.000309	0.0032	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL12A—multiple sclerosis	0.000309	0.0032	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—AQP4—multiple sclerosis	0.000294	0.00304	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—multiple sclerosis	0.000289	0.00299	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000286	0.00296	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—RGS1—multiple sclerosis	0.000286	0.00296	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	0.000281	0.00291	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—multiple sclerosis	0.000281	0.00291	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GPR65—multiple sclerosis	0.000271	0.00281	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	0.000265	0.00274	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—multiple sclerosis	0.000262	0.00272	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—multiple sclerosis	0.000257	0.00266	CbGpPWpGaD
Lenalidomide—ABCB1—brain—multiple sclerosis	0.000256	0.00294	CbGeAlD
Lenalidomide—PTGS2—S1P1 pathway—MAPK1—multiple sclerosis	0.00025	0.00259	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCR1—multiple sclerosis	0.000248	0.00257	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCL13—multiple sclerosis	0.000248	0.00257	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	0.000241	0.00249	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—TNF—multiple sclerosis	0.000238	0.00247	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000235	0.00244	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—multiple sclerosis	0.000233	0.00241	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.000209	0.00216	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCR2—multiple sclerosis	0.000204	0.00211	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000203	0.0021	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000194	0.00201	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000192	0.00199	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—IL6—multiple sclerosis	0.000192	0.00199	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000185	0.00192	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	0.000182	0.00189	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL3—multiple sclerosis	0.000177	0.00183	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTGER4—multiple sclerosis	0.00017	0.00176	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—multiple sclerosis	0.00017	0.00176	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL10—multiple sclerosis	0.000169	0.00175	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PGR—multiple sclerosis	0.000167	0.00173	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000167	0.00173	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCR3—multiple sclerosis	0.000164	0.0017	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CD28—multiple sclerosis	0.000163	0.00168	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	0.000161	0.00166	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCR2—multiple sclerosis	0.00016	0.00165	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—BDNF—multiple sclerosis	0.000152	0.00157	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—multiple sclerosis	0.000151	0.00156	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	0.00015	0.00156	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CNR1—multiple sclerosis	0.000147	0.00153	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD86—multiple sclerosis	0.000145	0.0015	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—ICAM1—multiple sclerosis	0.000142	0.00147	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	0.000142	0.00147	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL10—multiple sclerosis	0.000142	0.00147	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL4—multiple sclerosis	0.000141	0.00146	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL4—multiple sclerosis	0.000138	0.00143	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	0.000135	0.0014	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCL10—multiple sclerosis	0.000133	0.00137	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.00013	0.00134	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.00013	0.00134	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000129	0.00133	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—FAS—multiple sclerosis	0.000127	0.00132	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CCL2—multiple sclerosis	0.000127	0.00131	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	0.000126	0.00131	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	0.000126	0.00131	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	0.000125	0.00129	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	0.000123	0.00128	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—ALB—multiple sclerosis	0.000118	0.00122	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	0.000117	0.00122	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TLR4—multiple sclerosis	0.000117	0.00121	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CD86—multiple sclerosis	0.000116	0.0012	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL5—multiple sclerosis	0.000114	0.00118	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	0.000114	0.00118	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—ICAM1—multiple sclerosis	0.000112	0.00116	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—multiple sclerosis	0.00011	0.00114	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CD4—multiple sclerosis	0.000108	0.00112	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IFNG—multiple sclerosis	0.000108	0.00112	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SPP1—multiple sclerosis	0.000106	0.0011	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD80—multiple sclerosis	0.000106	0.00109	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000103	0.00107	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCR5—multiple sclerosis	0.000103	0.00107	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL2RA—multiple sclerosis	0.000101	0.00105	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCL2—multiple sclerosis	0.0001	0.00104	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL1B—multiple sclerosis	9.63e-05	0.000997	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	9.39e-05	0.000973	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APOE—multiple sclerosis	9.36e-05	0.00097	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	9.13e-05	0.000946	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	8.85e-05	0.000917	CbGpPWpGaD
Lenalidomide—Loss of consciousness—Dexamethasone—multiple sclerosis	8.85e-05	0.000277	CcSEcCtD
Lenalidomide—Epistaxis—Methotrexate—multiple sclerosis	8.85e-05	0.000277	CcSEcCtD
Lenalidomide—Hypersensitivity—Mitoxantrone—multiple sclerosis	8.84e-05	0.000277	CcSEcCtD
Lenalidomide—Paraesthesia—Prednisolone—multiple sclerosis	8.84e-05	0.000277	CcSEcCtD
Lenalidomide—Tachycardia—Triamcinolone—multiple sclerosis	8.84e-05	0.000276	CcSEcCtD
Lenalidomide—Mental disorder—Prednisone—multiple sclerosis	8.82e-05	0.000276	CcSEcCtD
Lenalidomide—Nausea—Azathioprine—multiple sclerosis	8.82e-05	0.000276	CcSEcCtD
Lenalidomide—Tachycardia—Methylprednisolone—multiple sclerosis	8.82e-05	0.000276	CcSEcCtD
Lenalidomide—Skin disorder—Methylprednisolone—multiple sclerosis	8.78e-05	0.000274	CcSEcCtD
Lenalidomide—Erythema—Prednisone—multiple sclerosis	8.77e-05	0.000274	CcSEcCtD
Lenalidomide—Malnutrition—Prednisone—multiple sclerosis	8.77e-05	0.000274	CcSEcCtD
Lenalidomide—Hyperhidrosis—Triamcinolone—multiple sclerosis	8.76e-05	0.000274	CcSEcCtD
Lenalidomide—Agranulocytosis—Methotrexate—multiple sclerosis	8.75e-05	0.000274	CcSEcCtD
Lenalidomide—Hyperhidrosis—Methylprednisolone—multiple sclerosis	8.74e-05	0.000273	CcSEcCtD
Lenalidomide—Hypertension—Dexamethasone—multiple sclerosis	8.69e-05	0.000272	CcSEcCtD
Lenalidomide—Hypertension—Betamethasone—multiple sclerosis	8.69e-05	0.000272	CcSEcCtD
Lenalidomide—Asthenia—Mitoxantrone—multiple sclerosis	8.61e-05	0.000269	CcSEcCtD
Lenalidomide—Myalgia—Betamethasone—multiple sclerosis	8.57e-05	0.000268	CcSEcCtD
Lenalidomide—Myalgia—Dexamethasone—multiple sclerosis	8.57e-05	0.000268	CcSEcCtD
Lenalidomide—Anxiety—Dexamethasone—multiple sclerosis	8.54e-05	0.000267	CcSEcCtD
Lenalidomide—Anxiety—Betamethasone—multiple sclerosis	8.54e-05	0.000267	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IFNG—multiple sclerosis	8.54e-05	0.000884	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	8.49e-05	0.000879	CbGpPWpGaD
Lenalidomide—Discomfort—Dexamethasone—multiple sclerosis	8.47e-05	0.000265	CcSEcCtD
Lenalidomide—Discomfort—Betamethasone—multiple sclerosis	8.47e-05	0.000265	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CD80—multiple sclerosis	8.47e-05	0.000877	CbGpPWpGaD
Lenalidomide—Haemoglobin—Methotrexate—multiple sclerosis	8.46e-05	0.000265	CcSEcCtD
Lenalidomide—Hypotension—Methylprednisolone—multiple sclerosis	8.44e-05	0.000264	CcSEcCtD
Lenalidomide—Pain—Prednisolone—multiple sclerosis	8.42e-05	0.000263	CcSEcCtD
Lenalidomide—Haemorrhage—Methotrexate—multiple sclerosis	8.42e-05	0.000263	CcSEcCtD
Lenalidomide—Hepatitis—Methotrexate—multiple sclerosis	8.42e-05	0.000263	CcSEcCtD
Lenalidomide—Pharyngitis—Methotrexate—multiple sclerosis	8.36e-05	0.000261	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	8.34e-05	0.000864	CbGpPWpGaD
Lenalidomide—Urinary tract disorder—Methotrexate—multiple sclerosis	8.31e-05	0.00026	CcSEcCtD
Lenalidomide—Vision blurred—Prednisone—multiple sclerosis	8.26e-05	0.000258	CcSEcCtD
Lenalidomide—Urethral disorder—Methotrexate—multiple sclerosis	8.25e-05	0.000258	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	8.25e-05	0.000258	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	8.23e-05	0.000257	CcSEcCtD
Lenalidomide—Oedema—Dexamethasone—multiple sclerosis	8.22e-05	0.000257	CcSEcCtD
Lenalidomide—Oedema—Betamethasone—multiple sclerosis	8.22e-05	0.000257	CcSEcCtD
Lenalidomide—Diarrhoea—Mitoxantrone—multiple sclerosis	8.21e-05	0.000257	CcSEcCtD
Lenalidomide—Insomnia—Triamcinolone—multiple sclerosis	8.19e-05	0.000256	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—SRM—multiple sclerosis	8.19e-05	0.000848	CbGpPWpGaD
Lenalidomide—Insomnia—Methylprednisolone—multiple sclerosis	8.17e-05	0.000256	CcSEcCtD
Lenalidomide—Infection—Dexamethasone—multiple sclerosis	8.16e-05	0.000255	CcSEcCtD
Lenalidomide—Infection—Betamethasone—multiple sclerosis	8.16e-05	0.000255	CcSEcCtD
Lenalidomide—Ill-defined disorder—Prednisone—multiple sclerosis	8.14e-05	0.000254	CcSEcCtD
Lenalidomide—Paraesthesia—Triamcinolone—multiple sclerosis	8.13e-05	0.000254	CcSEcCtD
Lenalidomide—Feeling abnormal—Prednisolone—multiple sclerosis	8.12e-05	0.000254	CcSEcCtD
Lenalidomide—Paraesthesia—Methylprednisolone—multiple sclerosis	8.11e-05	0.000254	CcSEcCtD
Lenalidomide—Visual impairment—Methotrexate—multiple sclerosis	8.11e-05	0.000254	CcSEcCtD
Lenalidomide—Anaemia—Prednisone—multiple sclerosis	8.1e-05	0.000253	CcSEcCtD
Lenalidomide—Shock—Dexamethasone—multiple sclerosis	8.08e-05	0.000253	CcSEcCtD
Lenalidomide—Shock—Betamethasone—multiple sclerosis	8.08e-05	0.000253	CcSEcCtD
Lenalidomide—Dyspnoea—Triamcinolone—multiple sclerosis	8.07e-05	0.000253	CcSEcCtD
Lenalidomide—Nervous system disorder—Betamethasone—multiple sclerosis	8.06e-05	0.000252	CcSEcCtD
Lenalidomide—Nervous system disorder—Dexamethasone—multiple sclerosis	8.06e-05	0.000252	CcSEcCtD
Lenalidomide—Agitation—Prednisone—multiple sclerosis	8.06e-05	0.000252	CcSEcCtD
Lenalidomide—Thrombocytopenia—Betamethasone—multiple sclerosis	8.05e-05	0.000252	CcSEcCtD
Lenalidomide—Thrombocytopenia—Dexamethasone—multiple sclerosis	8.05e-05	0.000252	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—POMC—multiple sclerosis	8.05e-05	0.000833	CbGpPWpGaD
Lenalidomide—Tachycardia—Dexamethasone—multiple sclerosis	8.02e-05	0.000251	CcSEcCtD
Lenalidomide—Tachycardia—Betamethasone—multiple sclerosis	8.02e-05	0.000251	CcSEcCtD
Lenalidomide—Angioedema—Prednisone—multiple sclerosis	8.01e-05	0.000251	CcSEcCtD
Lenalidomide—Dyspepsia—Triamcinolone—multiple sclerosis	7.97e-05	0.000249	CcSEcCtD
Lenalidomide—Erythema multiforme—Methotrexate—multiple sclerosis	7.96e-05	0.000249	CcSEcCtD
Lenalidomide—Dyspepsia—Methylprednisolone—multiple sclerosis	7.95e-05	0.000249	CcSEcCtD
Lenalidomide—Hyperhidrosis—Dexamethasone—multiple sclerosis	7.94e-05	0.000248	CcSEcCtD
Lenalidomide—Hyperhidrosis—Betamethasone—multiple sclerosis	7.94e-05	0.000248	CcSEcCtD
Lenalidomide—Malaise—Prednisone—multiple sclerosis	7.91e-05	0.000247	CcSEcCtD
Lenalidomide—Vertigo—Prednisone—multiple sclerosis	7.88e-05	0.000246	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CCL2—multiple sclerosis	7.87e-05	0.000815	CbGpPWpGaD
Lenalidomide—Eye disorder—Methotrexate—multiple sclerosis	7.87e-05	0.000246	CcSEcCtD
Lenalidomide—Syncope—Prednisone—multiple sclerosis	7.86e-05	0.000246	CcSEcCtD
Lenalidomide—Tinnitus—Methotrexate—multiple sclerosis	7.85e-05	0.000245	CcSEcCtD
Lenalidomide—Anorexia—Betamethasone—multiple sclerosis	7.83e-05	0.000245	CcSEcCtD
Lenalidomide—Anorexia—Dexamethasone—multiple sclerosis	7.83e-05	0.000245	CcSEcCtD
Lenalidomide—Urticaria—Prednisolone—multiple sclerosis	7.82e-05	0.000245	CcSEcCtD
Lenalidomide—Cardiac disorder—Methotrexate—multiple sclerosis	7.81e-05	0.000244	CcSEcCtD
Lenalidomide—Fatigue—Triamcinolone—multiple sclerosis	7.81e-05	0.000244	CcSEcCtD
Lenalidomide—Fatigue—Methylprednisolone—multiple sclerosis	7.79e-05	0.000244	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—multiple sclerosis	7.78e-05	0.000806	CbGpPWpGaD
Lenalidomide—Pain—Triamcinolone—multiple sclerosis	7.74e-05	0.000242	CcSEcCtD
Lenalidomide—Loss of consciousness—Prednisone—multiple sclerosis	7.71e-05	0.000241	CcSEcCtD
Lenalidomide—Hypotension—Dexamethasone—multiple sclerosis	7.68e-05	0.00024	CcSEcCtD
Lenalidomide—Hypotension—Betamethasone—multiple sclerosis	7.68e-05	0.00024	CcSEcCtD
Lenalidomide—Angiopathy—Methotrexate—multiple sclerosis	7.64e-05	0.000239	CcSEcCtD
Lenalidomide—Vomiting—Mitoxantrone—multiple sclerosis	7.63e-05	0.000239	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL1B—multiple sclerosis	7.61e-05	0.000788	CbGpPWpGaD
Lenalidomide—Immune system disorder—Methotrexate—multiple sclerosis	7.6e-05	0.000238	CcSEcCtD
Lenalidomide—Mediastinal disorder—Methotrexate—multiple sclerosis	7.59e-05	0.000237	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL2—multiple sclerosis	7.59e-05	0.000786	CbGpPWpGaD
Lenalidomide—Hypertension—Prednisone—multiple sclerosis	7.57e-05	0.000237	CcSEcCtD
Lenalidomide—Rash—Mitoxantrone—multiple sclerosis	7.57e-05	0.000237	CcSEcCtD
Lenalidomide—Dermatitis—Mitoxantrone—multiple sclerosis	7.56e-05	0.000236	CcSEcCtD
Lenalidomide—Chills—Methotrexate—multiple sclerosis	7.55e-05	0.000236	CcSEcCtD
Lenalidomide—Headache—Mitoxantrone—multiple sclerosis	7.52e-05	0.000235	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	7.49e-05	0.000234	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	7.49e-05	0.000234	CcSEcCtD
Lenalidomide—Arthralgia—Prednisone—multiple sclerosis	7.47e-05	0.000233	CcSEcCtD
Lenalidomide—Myalgia—Prednisone—multiple sclerosis	7.47e-05	0.000233	CcSEcCtD
Lenalidomide—Feeling abnormal—Triamcinolone—multiple sclerosis	7.46e-05	0.000233	CcSEcCtD
Lenalidomide—Feeling abnormal—Methylprednisolone—multiple sclerosis	7.45e-05	0.000233	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	7.44e-05	0.00077	CbGpPWpGaD
Lenalidomide—Anxiety—Prednisone—multiple sclerosis	7.44e-05	0.000233	CcSEcCtD
Lenalidomide—Alopecia—Methotrexate—multiple sclerosis	7.44e-05	0.000233	CcSEcCtD
Lenalidomide—Insomnia—Dexamethasone—multiple sclerosis	7.43e-05	0.000232	CcSEcCtD
Lenalidomide—Insomnia—Betamethasone—multiple sclerosis	7.43e-05	0.000232	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	7.41e-05	0.000232	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IL2—multiple sclerosis	7.41e-05	0.000768	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	7.39e-05	0.000231	CcSEcCtD
Lenalidomide—Paraesthesia—Dexamethasone—multiple sclerosis	7.38e-05	0.000231	CcSEcCtD
Lenalidomide—Paraesthesia—Betamethasone—multiple sclerosis	7.38e-05	0.000231	CcSEcCtD
Lenalidomide—Discomfort—Prednisone—multiple sclerosis	7.38e-05	0.000231	CcSEcCtD
Lenalidomide—Mental disorder—Methotrexate—multiple sclerosis	7.38e-05	0.000231	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	7.33e-05	0.000759	CbGpPWpGaD
Lenalidomide—Erythema—Methotrexate—multiple sclerosis	7.33e-05	0.000229	CcSEcCtD
Lenalidomide—Malnutrition—Methotrexate—multiple sclerosis	7.33e-05	0.000229	CcSEcCtD
Lenalidomide—Hypersensitivity—Prednisolone—multiple sclerosis	7.26e-05	0.000227	CcSEcCtD
Lenalidomide—Dyspepsia—Betamethasone—multiple sclerosis	7.23e-05	0.000226	CcSEcCtD
Lenalidomide—Dyspepsia—Dexamethasone—multiple sclerosis	7.23e-05	0.000226	CcSEcCtD
Lenalidomide—Urticaria—Triamcinolone—multiple sclerosis	7.19e-05	0.000225	CcSEcCtD
Lenalidomide—Urticaria—Methylprednisolone—multiple sclerosis	7.18e-05	0.000224	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP9—multiple sclerosis	7.18e-05	0.000743	CbGpPWpGaD
Lenalidomide—Dysgeusia—Methotrexate—multiple sclerosis	7.18e-05	0.000224	CcSEcCtD
Lenalidomide—Body temperature increased—Triamcinolone—multiple sclerosis	7.16e-05	0.000224	CcSEcCtD
Lenalidomide—Oedema—Prednisone—multiple sclerosis	7.16e-05	0.000224	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TYK2—multiple sclerosis	7.15e-05	0.00074	CbGpPWpGaD
Lenalidomide—Abdominal pain—Methylprednisolone—multiple sclerosis	7.14e-05	0.000223	CcSEcCtD
Lenalidomide—Decreased appetite—Betamethasone—multiple sclerosis	7.14e-05	0.000223	CcSEcCtD
Lenalidomide—Decreased appetite—Dexamethasone—multiple sclerosis	7.14e-05	0.000223	CcSEcCtD
Lenalidomide—Nausea—Mitoxantrone—multiple sclerosis	7.13e-05	0.000223	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	7.12e-05	0.000737	CbGpPWpGaD
Lenalidomide—Infection—Prednisone—multiple sclerosis	7.11e-05	0.000222	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	7.09e-05	0.000222	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	7.09e-05	0.000222	CcSEcCtD
Lenalidomide—Back pain—Methotrexate—multiple sclerosis	7.09e-05	0.000222	CcSEcCtD
Lenalidomide—Fatigue—Dexamethasone—multiple sclerosis	7.08e-05	0.000222	CcSEcCtD
Lenalidomide—Fatigue—Betamethasone—multiple sclerosis	7.08e-05	0.000222	CcSEcCtD
Lenalidomide—Shock—Prednisone—multiple sclerosis	7.04e-05	0.00022	CcSEcCtD
Lenalidomide—Pain—Dexamethasone—multiple sclerosis	7.03e-05	0.00022	CcSEcCtD
Lenalidomide—Pain—Betamethasone—multiple sclerosis	7.03e-05	0.00022	CcSEcCtD
Lenalidomide—Nervous system disorder—Prednisone—multiple sclerosis	7.02e-05	0.000219	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—multiple sclerosis	6.99e-05	0.000723	CbGpPWpGaD
Lenalidomide—Tachycardia—Prednisone—multiple sclerosis	6.98e-05	0.000218	CcSEcCtD
Lenalidomide—Skin disorder—Prednisone—multiple sclerosis	6.95e-05	0.000217	CcSEcCtD
Lenalidomide—Hyperhidrosis—Prednisone—multiple sclerosis	6.92e-05	0.000216	CcSEcCtD
Lenalidomide—Vision blurred—Methotrexate—multiple sclerosis	6.91e-05	0.000216	CcSEcCtD
Lenalidomide—Anorexia—Prednisone—multiple sclerosis	6.82e-05	0.000213	CcSEcCtD
Lenalidomide—Ill-defined disorder—Methotrexate—multiple sclerosis	6.8e-05	0.000213	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—multiple sclerosis	6.77e-05	0.000212	CcSEcCtD
Lenalidomide—Feeling abnormal—Dexamethasone—multiple sclerosis	6.77e-05	0.000212	CcSEcCtD
Lenalidomide—Feeling abnormal—Betamethasone—multiple sclerosis	6.77e-05	0.000212	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Dexamethasone—multiple sclerosis	6.72e-05	0.00021	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Betamethasone—multiple sclerosis	6.72e-05	0.00021	CcSEcCtD
Lenalidomide—Hypersensitivity—Triamcinolone—multiple sclerosis	6.67e-05	0.000209	CcSEcCtD
Lenalidomide—Hypersensitivity—Methylprednisolone—multiple sclerosis	6.66e-05	0.000208	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—multiple sclerosis	6.61e-05	0.000207	CcSEcCtD
Lenalidomide—Vertigo—Methotrexate—multiple sclerosis	6.58e-05	0.000206	CcSEcCtD
Lenalidomide—Leukopenia—Methotrexate—multiple sclerosis	6.56e-05	0.000205	CcSEcCtD
Lenalidomide—Urticaria—Betamethasone—multiple sclerosis	6.53e-05	0.000204	CcSEcCtD
Lenalidomide—Urticaria—Dexamethasone—multiple sclerosis	6.53e-05	0.000204	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Prednisone—multiple sclerosis	6.52e-05	0.000204	CcSEcCtD
Lenalidomide—Dizziness—Prednisolone—multiple sclerosis	6.51e-05	0.000204	CcSEcCtD
Lenalidomide—Asthenia—Triamcinolone—multiple sclerosis	6.5e-05	0.000203	CcSEcCtD
Lenalidomide—Body temperature increased—Dexamethasone—multiple sclerosis	6.5e-05	0.000203	CcSEcCtD
Lenalidomide—Abdominal pain—Betamethasone—multiple sclerosis	6.5e-05	0.000203	CcSEcCtD
Lenalidomide—Body temperature increased—Betamethasone—multiple sclerosis	6.5e-05	0.000203	CcSEcCtD
Lenalidomide—Abdominal pain—Dexamethasone—multiple sclerosis	6.5e-05	0.000203	CcSEcCtD
Lenalidomide—Asthenia—Methylprednisolone—multiple sclerosis	6.48e-05	0.000203	CcSEcCtD
Lenalidomide—Insomnia—Prednisone—multiple sclerosis	6.47e-05	0.000202	CcSEcCtD
Lenalidomide—Paraesthesia—Prednisone—multiple sclerosis	6.43e-05	0.000201	CcSEcCtD
Lenalidomide—Pruritus—Triamcinolone—multiple sclerosis	6.41e-05	0.0002	CcSEcCtD
Lenalidomide—Cough—Methotrexate—multiple sclerosis	6.39e-05	0.0002	CcSEcCtD
Lenalidomide—Pruritus—Methylprednisolone—multiple sclerosis	6.39e-05	0.0002	CcSEcCtD
Lenalidomide—PTGS2—Disease—GPC5—multiple sclerosis	6.3e-05	0.000653	CbGpPWpGaD
Lenalidomide—Dyspepsia—Prednisone—multiple sclerosis	6.3e-05	0.000197	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	6.28e-05	0.00065	CbGpPWpGaD
Lenalidomide—Arthralgia—Methotrexate—multiple sclerosis	6.24e-05	0.000195	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—multiple sclerosis	6.24e-05	0.000195	CcSEcCtD
Lenalidomide—Myalgia—Methotrexate—multiple sclerosis	6.24e-05	0.000195	CcSEcCtD
Lenalidomide—Decreased appetite—Prednisone—multiple sclerosis	6.22e-05	0.000195	CcSEcCtD
Lenalidomide—Rash—Prednisolone—multiple sclerosis	6.21e-05	0.000194	CcSEcCtD
Lenalidomide—Dermatitis—Prednisolone—multiple sclerosis	6.2e-05	0.000194	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	6.2e-05	0.000194	CcSEcCtD
Lenalidomide—Diarrhoea—Methylprednisolone—multiple sclerosis	6.18e-05	0.000193	CcSEcCtD
Lenalidomide—Fatigue—Prednisone—multiple sclerosis	6.17e-05	0.000193	CcSEcCtD
Lenalidomide—Headache—Prednisolone—multiple sclerosis	6.17e-05	0.000193	CcSEcCtD
Lenalidomide—Discomfort—Methotrexate—multiple sclerosis	6.16e-05	0.000193	CcSEcCtD
Lenalidomide—Constipation—Prednisone—multiple sclerosis	6.12e-05	0.000191	CcSEcCtD
Lenalidomide—Confusional state—Methotrexate—multiple sclerosis	6.03e-05	0.000189	CcSEcCtD
Lenalidomide—Dizziness—Triamcinolone—multiple sclerosis	5.99e-05	0.000187	CcSEcCtD
Lenalidomide—Dizziness—Methylprednisolone—multiple sclerosis	5.98e-05	0.000187	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IL2—multiple sclerosis	5.95e-05	0.000616	CbGpPWpGaD
Lenalidomide—Infection—Methotrexate—multiple sclerosis	5.94e-05	0.000186	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—multiple sclerosis	5.93e-05	0.000614	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TGFB1—multiple sclerosis	5.92e-05	0.000613	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Prednisone—multiple sclerosis	5.9e-05	0.000184	CcSEcCtD
Lenalidomide—Asthenia—Dexamethasone—multiple sclerosis	5.9e-05	0.000184	CcSEcCtD
Lenalidomide—Asthenia—Betamethasone—multiple sclerosis	5.9e-05	0.000184	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—multiple sclerosis	5.87e-05	0.000183	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methotrexate—multiple sclerosis	5.86e-05	0.000183	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Prednisone—multiple sclerosis	5.85e-05	0.000183	CcSEcCtD
Lenalidomide—Nausea—Prednisolone—multiple sclerosis	5.85e-05	0.000183	CcSEcCtD
Lenalidomide—Pruritus—Dexamethasone—multiple sclerosis	5.81e-05	0.000182	CcSEcCtD
Lenalidomide—Pruritus—Betamethasone—multiple sclerosis	5.81e-05	0.000182	CcSEcCtD
Lenalidomide—Skin disorder—Methotrexate—multiple sclerosis	5.81e-05	0.000182	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—SRM—multiple sclerosis	5.81e-05	0.000601	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MAPK1—multiple sclerosis	5.8e-05	0.000601	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Methotrexate—multiple sclerosis	5.78e-05	0.000181	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	5.78e-05	0.000599	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP24A1—multiple sclerosis	5.77e-05	0.000598	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP27B1—multiple sclerosis	5.77e-05	0.000598	CbGpPWpGaD
Lenalidomide—Vomiting—Triamcinolone—multiple sclerosis	5.76e-05	0.00018	CcSEcCtD
Lenalidomide—Vomiting—Methylprednisolone—multiple sclerosis	5.75e-05	0.00018	CcSEcCtD
Lenalidomide—Rash—Triamcinolone—multiple sclerosis	5.71e-05	0.000179	CcSEcCtD
Lenalidomide—Dermatitis—Triamcinolone—multiple sclerosis	5.71e-05	0.000178	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—multiple sclerosis	5.7e-05	0.000178	CcSEcCtD
Lenalidomide—Rash—Methylprednisolone—multiple sclerosis	5.7e-05	0.000178	CcSEcCtD
Lenalidomide—Dermatitis—Methylprednisolone—multiple sclerosis	5.69e-05	0.000178	CcSEcCtD
Lenalidomide—Urticaria—Prednisone—multiple sclerosis	5.69e-05	0.000178	CcSEcCtD
Lenalidomide—Headache—Triamcinolone—multiple sclerosis	5.67e-05	0.000177	CcSEcCtD
Lenalidomide—Headache—Methylprednisolone—multiple sclerosis	5.66e-05	0.000177	CcSEcCtD
Lenalidomide—Abdominal pain—Prednisone—multiple sclerosis	5.66e-05	0.000177	CcSEcCtD
Lenalidomide—Body temperature increased—Prednisone—multiple sclerosis	5.66e-05	0.000177	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	5.64e-05	0.000584	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—multiple sclerosis	5.64e-05	0.000584	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MMP9—multiple sclerosis	5.63e-05	0.000583	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	5.63e-05	0.000583	CbGpPWpGaD
Lenalidomide—Diarrhoea—Dexamethasone—multiple sclerosis	5.62e-05	0.000176	CcSEcCtD
Lenalidomide—Diarrhoea—Betamethasone—multiple sclerosis	5.62e-05	0.000176	CcSEcCtD
Lenalidomide—Hypotension—Methotrexate—multiple sclerosis	5.59e-05	0.000175	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—multiple sclerosis	5.52e-05	0.000572	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	5.45e-05	0.00017	CcSEcCtD
Lenalidomide—Dizziness—Betamethasone—multiple sclerosis	5.43e-05	0.00017	CcSEcCtD
Lenalidomide—Dizziness—Dexamethasone—multiple sclerosis	5.43e-05	0.00017	CcSEcCtD
Lenalidomide—Insomnia—Methotrexate—multiple sclerosis	5.41e-05	0.000169	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—TNF—multiple sclerosis	5.4e-05	0.000559	CbGpPWpGaD
Lenalidomide—Nausea—Triamcinolone—multiple sclerosis	5.38e-05	0.000168	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—multiple sclerosis	5.37e-05	0.000168	CcSEcCtD
Lenalidomide—Nausea—Methylprednisolone—multiple sclerosis	5.37e-05	0.000168	CcSEcCtD
Lenalidomide—Dyspnoea—Methotrexate—multiple sclerosis	5.33e-05	0.000167	CcSEcCtD
Lenalidomide—Somnolence—Methotrexate—multiple sclerosis	5.32e-05	0.000166	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—GPC5—multiple sclerosis	5.28e-05	0.000547	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Prednisone—multiple sclerosis	5.27e-05	0.000165	CcSEcCtD
Lenalidomide—Dyspepsia—Methotrexate—multiple sclerosis	5.26e-05	0.000165	CcSEcCtD
Lenalidomide—Vomiting—Dexamethasone—multiple sclerosis	5.22e-05	0.000163	CcSEcCtD
Lenalidomide—Vomiting—Betamethasone—multiple sclerosis	5.22e-05	0.000163	CcSEcCtD
Lenalidomide—Decreased appetite—Methotrexate—multiple sclerosis	5.2e-05	0.000163	CcSEcCtD
Lenalidomide—Rash—Betamethasone—multiple sclerosis	5.18e-05	0.000162	CcSEcCtD
Lenalidomide—Rash—Dexamethasone—multiple sclerosis	5.18e-05	0.000162	CcSEcCtD
Lenalidomide—Dermatitis—Betamethasone—multiple sclerosis	5.18e-05	0.000162	CcSEcCtD
Lenalidomide—Dermatitis—Dexamethasone—multiple sclerosis	5.18e-05	0.000162	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	5.16e-05	0.000161	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—multiple sclerosis	5.16e-05	0.000161	CcSEcCtD
Lenalidomide—Headache—Dexamethasone—multiple sclerosis	5.15e-05	0.000161	CcSEcCtD
Lenalidomide—Headache—Betamethasone—multiple sclerosis	5.15e-05	0.000161	CcSEcCtD
Lenalidomide—Asthenia—Prednisone—multiple sclerosis	5.13e-05	0.000161	CcSEcCtD
Lenalidomide—Pain—Methotrexate—multiple sclerosis	5.11e-05	0.00016	CcSEcCtD
Lenalidomide—Pruritus—Prednisone—multiple sclerosis	5.06e-05	0.000158	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—STAT3—multiple sclerosis	5e-05	0.000518	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	4.97e-05	0.000515	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Methotrexate—multiple sclerosis	4.93e-05	0.000154	CcSEcCtD
Lenalidomide—Diarrhoea—Prednisone—multiple sclerosis	4.9e-05	0.000153	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methotrexate—multiple sclerosis	4.89e-05	0.000153	CcSEcCtD
Lenalidomide—Nausea—Betamethasone—multiple sclerosis	4.88e-05	0.000153	CcSEcCtD
Lenalidomide—Nausea—Dexamethasone—multiple sclerosis	4.88e-05	0.000153	CcSEcCtD
Lenalidomide—Urticaria—Methotrexate—multiple sclerosis	4.75e-05	0.000149	CcSEcCtD
Lenalidomide—Dizziness—Prednisone—multiple sclerosis	4.73e-05	0.000148	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—multiple sclerosis	4.73e-05	0.000148	CcSEcCtD
Lenalidomide—Body temperature increased—Methotrexate—multiple sclerosis	4.73e-05	0.000148	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MYC—multiple sclerosis	4.65e-05	0.000482	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TGFB1—multiple sclerosis	4.64e-05	0.00048	CbGpPWpGaD
Lenalidomide—Vomiting—Prednisone—multiple sclerosis	4.55e-05	0.000142	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MAPK1—multiple sclerosis	4.55e-05	0.000471	CbGpPWpGaD
Lenalidomide—Rash—Prednisone—multiple sclerosis	4.51e-05	0.000141	CcSEcCtD
Lenalidomide—Dermatitis—Prednisone—multiple sclerosis	4.51e-05	0.000141	CcSEcCtD
Lenalidomide—Headache—Prednisone—multiple sclerosis	4.48e-05	0.00014	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—multiple sclerosis	4.46e-05	0.000462	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Methotrexate—multiple sclerosis	4.41e-05	0.000138	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—RRM1—multiple sclerosis	4.37e-05	0.000453	CbGpPWpGaD
Lenalidomide—Asthenia—Methotrexate—multiple sclerosis	4.29e-05	0.000134	CcSEcCtD
Lenalidomide—Nausea—Prednisone—multiple sclerosis	4.25e-05	0.000133	CcSEcCtD
Lenalidomide—Pruritus—Methotrexate—multiple sclerosis	4.23e-05	0.000132	CcSEcCtD
Lenalidomide—PTGS2—Disease—RPL5—multiple sclerosis	4.1e-05	0.000424	CbGpPWpGaD
Lenalidomide—Diarrhoea—Methotrexate—multiple sclerosis	4.09e-05	0.000128	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—CYP27B1—multiple sclerosis	4.09e-05	0.000424	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP24A1—multiple sclerosis	4.09e-05	0.000424	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	4.03e-05	0.000418	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	4.02e-05	0.000417	CbGpPWpGaD
Lenalidomide—Dizziness—Methotrexate—multiple sclerosis	3.95e-05	0.000124	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	3.95e-05	0.000409	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SLC11A1—multiple sclerosis	3.92e-05	0.000406	CbGpPWpGaD
Lenalidomide—Vomiting—Methotrexate—multiple sclerosis	3.8e-05	0.000119	CcSEcCtD
Lenalidomide—Rash—Methotrexate—multiple sclerosis	3.77e-05	0.000118	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—multiple sclerosis	3.77e-05	0.000118	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	3.76e-05	0.000389	CbGpPWpGaD
Lenalidomide—Headache—Methotrexate—multiple sclerosis	3.75e-05	0.000117	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—GPC5—multiple sclerosis	3.74e-05	0.000387	CbGpPWpGaD
Lenalidomide—Nausea—Methotrexate—multiple sclerosis	3.55e-05	0.000111	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IL6—multiple sclerosis	3.5e-05	0.000362	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.39e-05	0.000351	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD28—multiple sclerosis	3.13e-05	0.000325	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—RRM1—multiple sclerosis	3.1e-05	0.000321	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.91e-05	0.000302	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.86e-05	0.000296	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.85e-05	0.000295	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.8e-05	0.00029	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.66e-05	0.000276	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.66e-05	0.000275	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—BCHE—multiple sclerosis	2.51e-05	0.00026	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD86—multiple sclerosis	2.24e-05	0.000232	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CCR5—multiple sclerosis	1.98e-05	0.000205	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HLA-A—multiple sclerosis	1.93e-05	0.0002	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOE—multiple sclerosis	1.8e-05	0.000187	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.79e-05	0.000185	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—BCHE—multiple sclerosis	1.78e-05	0.000184	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD80—multiple sclerosis	1.63e-05	0.000169	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOE—multiple sclerosis	1.51e-05	0.000156	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TYK2—multiple sclerosis	1.38e-05	0.000143	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—POMC—multiple sclerosis	1.3e-05	0.000134	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD4—multiple sclerosis	1.25e-05	0.000129	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALB—multiple sclerosis	1.18e-05	0.000123	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOE—multiple sclerosis	1.07e-05	0.000111	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—multiple sclerosis	9.64e-06	9.98e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—POMC—multiple sclerosis	9.2e-06	9.53e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—multiple sclerosis	8.96e-06	9.28e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFB1—multiple sclerosis	8.94e-06	9.26e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAPK1—multiple sclerosis	8.76e-06	9.08e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALB—multiple sclerosis	8.39e-06	8.69e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—multiple sclerosis	6.73e-06	6.97e-05	CbGpPWpGaD
